The tumor suppressor role of microRNA‑338‑3p in renal cell carcinoma

Huang,Yidong; Wu,Yang; Zeng,Li; Shan,Wei; Huang,Lugang

doi:10.3892/ol.2018.8914

The tumor suppressor role of microRNA‑338‑3p in renal cell carcinoma

Authors:
- Yidong Huang
- Yang Wu
- Li Zeng
- Wei Shan
- Lugang Huang
View Affiliations

Affiliations: Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 6, 2018 https://doi.org/10.3892/ol.2018.8914
Pages: 2195-2200
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human renal cell carcinoma (RCC) is the most common type of kidney malignancy in adults accounting for 2‑3% of all adult malignancies. In China, RCC accounts for ~0.5% of all cancer‑associated mortalities, ranking 16th among all cancer types. For early‑stage RCC, surgery is the recommended treatment. Molecularly targeted therapy is the preferred first‑line treatment for clear‑cell RCC. However, more potential targets are required. MicroRNA‑338‑3p (miR‑338‑3p) functions as a tumor suppressor in various cancers, but has not been studied in RCC. Accordingly, the present study investigated the role of miR‑338‑3p of RCC. It was demonstrated that miR‑338‑3p was present at low levels in RCC tissues. Also, overexpression of miR‑338‑3p inhibited cell proliferation and promoted cell apoptosis, and downregulation of miR‑338‑3p promoted cell proliferation. The 3' untranslated region of AKT serine/threonine kinase 3 was targeted by miR‑338‑3p. In conclusion, the data of the present study revealed the inhibitory function of miR‑338‑3p in RCC and suggested that miR‑338‑3p is novel therapeutic target for RCC, but further investigation is needed.

View Figures

View References

1	Perlman E, Grosfeld J, Togashi K and Boccon-Gibod L: Pathology and genetics of tumors of the urinary system and male genital organs. World Health Organization Classification of Tumours. 1st edition. IARC Press; Lyon, France; pp. 48–52. 2004
2	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
4	Gelb AB: Renal cell carcinoma: Current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 80:981–986. 1997. View Article : Google Scholar : PubMed/NCBI
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
6	Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, et al: Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 3:2792015.PubMed/NCBI
7	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
8	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
9	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
10	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
11	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
12	Nugent M: microRNA and bone cancer. Adv Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
13	Del Vescovo V and Denti MA: microRNA and lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sui GQ, Fei D, Guo F, Zhen X, Luo Q, Yin S and Wang H: MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3. Am J Cancer Res. 7:1177–1187. 2017.PubMed/NCBI
15	Zhang G, Zheng H, Zhang G, Cheng R, Lu C, Guo Y and Zhao G: MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2. Cancer Cell Int. 17:462017. View Article : Google Scholar : PubMed/NCBI
16	Zhang P, Shao G, Lin X, Liu Y and Yang Z: MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res. 7:53–63. 2017.PubMed/NCBI
17	Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y, Yi HM, Li H, Zhang Q, Chen WJ and Chen GH: Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother. 84:583–591. 2016. View Article : Google Scholar : PubMed/NCBI
18	Jin Y, Zhao M, Xie Q, Zhang H, Wang Q and Ma Q: MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. Int J Oncol. 47:1594–1602. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ and Li GX: MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol. 44:13–21. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
21	Song B, Zhang C, Li G, Jin G and Liu C: MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhou Q and Yu Y: Upregulated CDK16 expression in serous epithelial ovarian cancer cells. Med Sci Monit. 21:3409–3414. 2015. View Article : Google Scholar : PubMed/NCBI
23	Li H, Xu Y, Qiu W, Zhao D and Zhang Y: Tissue miR-193b as a novel biomarker for patients with ovarian cancer. Med Sci Monit. 21:3929–3934. 2015. View Article : Google Scholar : PubMed/NCBI
24	Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
25	Gai D, Haan E, Scholar M, Nicholl J and Yu S: Phenotypes of AKT3 deletion: A case report and literature review. Am J Med Genet A. 167A:174–179. 2015. View Article : Google Scholar : PubMed/NCBI
26	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
27	Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
28	Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H and Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 108:391–397. 2001. View Article : Google Scholar : PubMed/NCBI
29	Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD and Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 14:395–403. 2004. View Article : Google Scholar : PubMed/NCBI
30	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
31	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
32	Manning BD, Tee AR, Logsdon MN, Blenis J and Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 10:151–162. 2002. View Article : Google Scholar : PubMed/NCBI
33	Brunet A, Datta SR and Greenberg ME: Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 11:297–305. 2001. View Article : Google Scholar : PubMed/NCBI
34	Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, et al: Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci USA. 112:3421–3426. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kim M, Kim YY, Jee HJ, Bae SS, Jeong NY, Um JH and Yun J: Akt3 knockdown induces mitochondrial dysfunction in human cancer cells. Acta Biochim Biophys Sin (Shanghai). 48:447–453. 2016. View Article : Google Scholar : PubMed/NCBI